.webp)
Mines parasite genomes to discover protein therapeutics for autoimmune diseases.
Company Overview
Competitors
Parasite-Derived
Macregen, Coronado Biosciences.
AI Protein Discovery
Generate Biomedicines, Absci, Evozyne.
Autoimmune Biologics
AbbVie, Amgen, BMS, Janssen.
Immunology Platforms
Anokion, Sonoma Biotherapeutics.
Ditto Biosciences
's Moat:
98%+ of parasite immunomodulatory proteins are uncharacterized, giving Ditto a vast unexplored design space. The computational biology platform for mining parasite genomes is proprietary, and 40+ years of combined PhD expertise across Harvard, Berkeley, and UCSF in host-parasite biology is not easily assembled.
How They're Leveraging AI
AI Use Overview:
Using computational parasite genome mining for immunomodulatory proteins, ML-guided protein optimization for drug-like properties, and immunogenicity prediction modeling.
CellType
Simulates human biology with AI to predict drug effects and run virtual trials.
Google CEO Sundar Pichai highlighted their C2S-Scale 27B model for generating a novel cancer hypothesis that was later validated experimentally. CellType simulates human biology to predict drug effects using foundation models presented at ICML 2024, with all deals coming inbound from top-10 pharma. Yale professor turned down Google to build it.
Mango Medical
Automates surgical planning for orthopedic procedures from CT scans using agentic AI.
Surgical planning for shoulder replacements takes hours of manual CT scan interpretation. Mango automates it in seconds via API, already past $500K ARR before demo day, with an 8-figure LOI from a leading orthopedic company. Only company in YC W26 pursuing FDA 510(k) clearance.
Origin
Designs regulatory DNA that outperforms DeepMind for safer, more precise gene therapies.
Gene therapies need precise regulatory DNA elements to control where and when genes express. Origin's Axis model outperforms DeepMind's AlphaGenome by 6.7% on activity prediction, with free API access for researchers and pharma partnerships forming.
